Gottlieb also covers the FDA's new Rare Disease Framework Initiative and the latest on the measles outbreak in the CNBC interview.
Recap by typeshit. Full story at CNBC.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
In a JAMA Network Open study of 3,615 adults, GLP-1 use was 20.5% among cancer survivors versus 26.5% in those without cancer, even though survivors carried more heart and kidney risk.
Three posters on November 14 and 15 compare the preclinical pill with orforglipron in animal models. Rivus says it plans to file an IND in Q1 2027.
Loading…